INVIVYD, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
INVIVYD, INC. (IVVD) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $7.78 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-05
- INVIVYD, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $7.78M, a 82.36% decline from fiscal 2024.
- INVIVYD, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $44.07M, a 36.22% decline from fiscal 2023.
- INVIVYD, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $69.10M, a 1.17% increase from fiscal 2022.
- INVIVYD, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $68.30M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 7 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | $7.78M 10-K · filed 2026-03-05 | ||
| 2024-12-31 | $44.07M 10-K · filed 2026-03-05 | $44.10M 10-K · filed 2025-03-20 | |
| 2023-12-31 | $69.10M 10-K · filed 2025-03-20 | ||
| 2022-12-31 | $68.30M 10-K · filed 2024-03-28 | ||
| 2021-12-31 | $57.30M 8-K · filed 2024-02-09 | ||
| 2020-12-31 | $5.70M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |